Bristol Myers Squibb Acquires RayzeBio in $4.1B Deal
December 26, 2023
Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in an all-cash transaction, valuing the equity at approximately $4.1 billion. The deal is expected to close in the first half of 2024, subject to customary conditions, bringing RayzeBio’s actinium-based radiopharmaceutical platform and clinical pipeline into BMS’s oncology franchise.
- Buyers
- Bristol Myers Squibb
- Targets
- RayzeBio, Inc.
- Industry
- Biotechnology
- Location
- United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.